Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Veterans Crisis Line Badge
Go to the ORD website
Go to the QUERI website

IIR 08-124 – HSR&D Study

New | Current | Completed | DRA | DRE | Portfolios/Projects | Centers | Career Development Projects

IIR 08-124
Cost Effectiveness of Deep Brain Stimulation for Parkinson's Disease
Frances M. Weaver PhD MA BA
Edward Hines Jr. VA Hospital, Hines, IL
Hines, IL
Funding Period: August 2009 - July 2012

BACKGROUND/RATIONALE:
Parkinson's disease (PD) is the second most common neuro-degenerative disease in the United States (US) after Alzheimer's disease (Tanner & Goldman, 1992). For PD patients who suffer from the long-term complications of medication management (i.e., levodopa), and experience decline in function, deep brain stimulation (DBS) is accepted as a surgical alternative to symptom management (Volkman, 2004, Weaver et al. 2009; Follett et al. 2010). Stimulation of the subthalamic nucleus (STN) or the internal globus pallidum (GPi) have been shown to be efficacious in relieving motor fluctuations and dyskinesias associated with PD (Volkman, 2004, Follett et al. 2010). However, the choice of surgical site may impact other outcomes including costs of care and health-related quality of life. Evidence from previous small uncontrolled studies has found that STN DBS usually results in a substantial decrease in PD medications compared with GPi DBS (Volkman, 2004; Weaver, et al., 2005). Because PD medication costs are approximately $4,500 per patient annually before DBS (Tomaszewski & Holloway, 2001), reduction in medication could result in substantial cost savings from STN over GPi DBS. Moreover, because GPi DBS involves stimulation of a larger area of the brain than STN DBS, GPi DBS may require greater stimulation energy resulting in more frequent replacement of the battery, at a cost of $18,000 (2007 dollars; Medtronic Neurological). However, there have been reports of more adverse events including mood and behavior changes requiring hospitalization and medications following STN than GPi DBS (Vitek, 2002). While previous smaller studies have identified potential differences in cost and quality of life outcomes between the surgical sites, these differences have not been confirmed in a large multi-site randomized controlled trial. The proposed study addressed this gap and provided information about the costs and consequences resulting from the choice of surgical site for DBS.
The goal of this study was to examine the costs and effectiveness of best medical therapy vs. deep brain stimulation (Phase 1) and for STN vs. GPi DBS (Phase II) by capitalizing on the multi-site VA Cooperative Studies Program (CSP) randomized trial of surgery for persons with PD (CSP 468; Weaver et al. 2009; 2012; Follett et al. 2010). The proposed study took advantage of the data from the CSP 468 study to examine health care costs, quality of life and cost-effectiveness up to 3 years post surgery for veterans and non-veterans who receive DBS.

OBJECTIVE(S):
Our primary aims were:
1. To estimate the total and disease-specific costs of Parkinson's disease-related care for patients following STN vs. GPi DBS up to 3 years post surgery;
2. To determine effectiveness between patients receiving STN vs. GPi DBS up to 3 years following surgery; and
3.To estimate the cost-effectiveness of STN vs. GPi DBS up to 3 years following surgery.
Our secondary aims included:
1. To compare the costs of care for patients receiving best medical therapy (BMT) to those who underwent DBS at 6 months;
2. To compare the effectiveness of best medical therapy to DBS at 6 months; and
3. To examine costs and effectiveness by age (<70 and 70+ years) and disease stage.


METHODS:
This was a secondary data analysis study to determine cost-effectiveness. We supplemented data from the VA cooperative studies (#468) with utilization and cost data extracted from VA administrative files for Veterans. We also requested Medicare and Medicaid claims data for our entire cohort. Utilization data were merged with patient study data including demographics, intervention data and quality of well-being to create an analysis file.

FINDINGS/RESULTS:
Results are provided for the Veteran cohort; analyses are ongoing for the non-Veteran patients. Participants included 77 Veterans who received BMT and 70 Veterans who underwent DBS in Phase I. They had a mean age of 62 years, 97% were male and 99% white. Excluding the DBS procedure, DBS patients utilized more outpatient visits (13.7 v. 8.4; p=0.0025), less 30-day PD medication prescriptions (13.8 v. 16.9; p<0.34) and more patients received DME (61% v. 25%; p<0.0001) than the BMT group over 6 months. While levodopa equivalents were higher for BMT than DBS (1,398 v.1, 101; p=0.005); PD medication costs did not differ by BMT v. DBS ($1589 v. $1750; p=0.55).
In Phase II, 85 patients received GPi and 76 received STN DBS. Their average age was 61 years old and 99% were white. There was no difference in initial costs for DBS procedure for GPi v. STN ($54,554 v. $50,752; p=0.15). Although the cost of the initial DBS procedure did not differ by target, total costs over 3 years (excluding travel and caregiver costs) was significantly higher for GPi than STN patients ($140,401 v. $117,892; p=0.041). The greater costs for GPi were due to greater costs of PD follow-up procedures ($18,470 v. $8,797; p=0.012) and medication costs ($7320 v. $5091; p=0.006).
The $22,509 greater costs for the GPi group is likely due to in large part to a larger number of reoperations for explanation and/or replacement of some component(s) of the DBS device for GPi than STN patients. At three years of follow-up, quality-adjusted life years (QALYs) were similar GPi and STN patients (1.153 v. 1.093 QALYs; p=0.38).

IMPACT:
Health care utilization and costs were very similar by group over three years following DBS. The battery life is shorter for the GPi patients, on average, due to the higher frequency required. Thus, battery replacement is likely to occur sooner in GPi patients. Medication costs also were lower for the STN patients, but accounted for a 5% of total costs.

PUBLICATIONS:

Journal Articles

  1. Wong JK, Cauraugh JH, Ho KWD, Broderick M, Ramirez-Zamora A, Almeida L, Wagle Shukla A, Wilson CA, de Bie RM, Weaver FM, Kang N, Okun MS. STN vs. GPi deep brain stimulation for tremor suppression in Parkinson disease: A systematic review and meta-analysis. Parkinsonism & Related Disorders. 2019 Jan 1; 58:56-62.
  2. Westbay LC, Cao L, Burnett-Zeigler I, Reizine N, Barton B, Ippolito D, Weaver FM, Stroupe KT. Mental Health-Related Healthcare Use Following Bilateral Deep Brain Stimulation For Parkinson's Disease. Journal of Parkinson's disease. 2015 Jan 1; 5(3):497-504.
  3. Stroupe KT, Weaver FM, Cao L, Ippolito D, Barton BR, Burnett-Zeigler IE, Holloway RG, Vickrey BG, Simuni T, Follett KA. Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites. Movement Disorders : Official Journal of The Movement Disorder Society. 2014 Nov 1; 29(13):1666-74.
  4. Weaver FM, Stroupe KT, Cao L, Holloway RG, Vickrey BG, Simuni T, Hendricks A, Ippolito D. Parkinson's disease medication use and costs following deep brain stimulation. Movement Disorders : Official Journal of The Movement Disorder Society. 2012 Sep 15; 27(11):1398-403.


DRA: Health Systems, Neurodegenerative Diseases, Aging, Older Veterans' Health and Care
DRE: Treatment - Observational
Keywords: Cost effectiveness, Cost-Effectiveness, Effectiveness, Parkinson's disease, Quality of Care, Quality of life
MeSH Terms: none

Questions about the HSR&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.